Hypersensitivity of Ph-positive lymphoid cell lines to rapamycin: Possible clinical application of mTOR inhibitor

C Hirase, Y Maeda, S Takai, A Kanamaru - Leukemia research, 2009 - Elsevier
The BCR/ABL tyrosine kinase inhibitor, imatinib mesylate, has shown substantial effects in
chronic myelogenous leukemia (CML) and Ph-positive acute lymphoblastic leukemia (Ph+
ALL). However, most patients relapse after an initial clinical response, indicating that drug
resistance is a major problem in patients on imatinib. The most important obstacle that
should be overcome in imatinib resistance is the development of a method of treatment for
cases that have the point mutation, T315I, in the ABL kinase domain. In this study, we …